Jeffrey Tate, Chief Operating Officer at Cyclo Therapeutics, Inc. (CYTH), bought 3,000 shares at $2.12 ($6K) on 2022-05-16, disclosed to the SEC on 2022-05-16.
Open-market purchase of $6k CYTH by Chief Operating Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| CYTH | BUY | 2021-03-30 | $15K | — | Filing → |